Outlook Therapeutics annual operating margin
2015
2016
2017
2018
2019
2025
Outlook Therapeutics's operating margin was −4,744.25% for fiscal 2025.
View full Outlook Therapeutics company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-09-30 | −4,744.25% | −4298.65 pp |
| 2019 | 2019-09-30 | −445.60% | +514.52 pp |
| 2018 | 2018-09-30 | −960.12% | −18.76 pp |
| 2017 | 2017-09-30 | −941.36% | +781.94 pp |
| 2016 | 2016-09-30 | −1,723.30% | −831.17 pp |
| 2015 | 2015-09-30 | −892.13% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q3 2025 | 2025-06-30 | −1,046.20% | −85.42 pp |
| Q4 2019 | 2019-09-30 | −216.83% | +1391.39 pp |
| Q3 2019 | 2019-06-30 | −966.72% | −31.37 pp |
| Q2 2019 | 2019-03-31 | −1,201.86% | −316.89 pp |
| Q1 2019 | 2018-12-31 | −960.78% | −548.84 pp |
| Q4 2018 | 2018-09-30 | −1,608.21% | −1507.92 pp |
| Q3 2018 | 2018-06-30 | −935.35% | +1484.79 pp |
| Q2 2018 | 2018-03-31 | −884.97% | +1700.63 pp |
| Q1 2018 | 2017-12-31 | −411.95% | +5458.36 pp |
| Q4 2017 | 2017-09-30 | −100.29% | +1910.74 pp |
| Q3 2017 | 2017-06-30 | −2,420.14% | +2030.81 pp |
| Q2 2017 | 2017-03-31 | −2,585.60% | −2288.69 pp |
| Q1 2017 | 2016-12-31 | −5,870.30% | −4220.56 pp |
| Q4 2016 | 2016-09-30 | −2,011.04% | −1158.01 pp |
| Q3 2016 | 2016-06-30 | −4,450.95% | −1621.73 pp |
| Q2 2016 | 2016-03-31 | −296.91% | — |
| Q1 2016 | 2015-12-31 | −1,649.75% | — |
| Q3 2015 | 2015-06-30 | −853.02% | — |
| Q2 2015 | 2015-03-31 | −2,829.23% | — |
Over the last five reported fiscal years, Outlook Therapeutics's operating margin decreased from −892.13% to −4,744.25%, a change of −3852.12 percentage points. The latest reported quarter, Q3 2025, shows −1,046.20%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Outlook Therapeutics filings at SEC.gov ↗